US Broker Ratings

LifeStance Health Group, Inc. (LFST) Stock Analysis: 19% Upside Potential and Strong Buy Ratings

LifeStance Health Group, Inc. (NASDAQ: LFST), a prominent player in the healthcare sector, is capturing investor attention with its robust growth prospects and a notable potential..

Apellis Pharmaceuticals (APLS) Stock Analysis: A 50% Upside Potential in the Biotech Sector

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS), a key player in the biotechnology sector, presents a compelling opportunity for investors with its promising pipeline and strategic collaborations. With..

Perrigo Company plc (PRGO) Stock Analysis: Exploring a 40.56% Upside Potential for Investors

Perrigo Company plc (NYSE: PRGO), a stalwart in the healthcare sector, primarily operates within the drug manufacturing space with a focus on both specialty and generic..

CG Oncology, Inc. (CGON) Stock Analysis: Unveiling a Potential 42% Upside in the Biotech Space

CG Oncology, Inc. (NASDAQ: CGON) is drawing significant attention from the investment community, not only due to its promising pipeline in the oncology sector but also..

Alvotech (ALVO) Stock Analysis: Unpacking a Potential 349.63% Upside

Alvotech (NASDAQ: ALVO), a Luxembourg-based healthcare company specializing in biosimilar medicines, is drawing significant investor attention due to its potential upside of 349.63%. With a market..

QuidelOrtho Corporation (QDEL) Stock Analysis: Navigating Growth Challenges with an Eye on a 12.91% Upside

QuidelOrtho Corporation (NASDAQ: QDEL), a key player in the healthcare sector specializing in medical devices, offers a fascinating valuation narrative for investors intrigued by the intricacies..

Belite Bio, Inc (BLTE) Stock Analysis: A Biotech Gem with 19.70% Upside Potential

Belite Bio, Inc (BLTE), a San Diego-based clinical-stage biopharmaceutical company, is capturing investor attention with its innovative approach to treating retinal degenerative eye diseases and other..

Mirum Pharmaceuticals, Inc. (MIRM) Investor Outlook: Promising Upside with 47.2% Revenue Growth

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical firm based in Foster City, California, is attracting significant interest from investors with its focus on developing groundbreaking therapies..

Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: A 52.66% Potential Upside Beckons Investors

As the biotechnology sector continues to capture investor attention with its cutting-edge innovations and high-growth potential, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) stands out with a compelling..

Warby Parker Inc. (WRBY) Stock Analysis: Revenue Growth and Analyst Confidence Signal Potential for Investors

Warby Parker Inc. (NYSE: WRBY) is capturing investor attention in the healthcare sector, specifically within the medical instruments and supplies industry. With a market cap of..

PTC Therapeutics, Inc. (PTCT) Stock Analysis: Navigating Growth in Rare Disease Biotech with a 6.24% Upside Potential

PTC Therapeutics, Inc. (NASDAQ: PTCT) stands out in the biotechnology sector as a promising player focused on rare disorders. With a market capitalization of $6.23 billion,..

Surgery Partners, Inc. (SGRY) Investor Outlook: Analyzing a 56% Potential Upside Amid Strong Buy Ratings

Surgery Partners, Inc. (NASDAQ: SGRY), a prominent player in the healthcare sector specializing in medical care facilities, presents an intriguing investment opportunity. With a market capitalization..

Catalyst Pharmaceuticals (CPRX) Stock Analysis: A 50% Upside Potential in the Biotech Arena

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is capturing investor interest with its promising upside potential of 50.12%, based on current analyst ratings. As a commercial-stage biopharmaceutical company,..

Viking Therapeutics, Inc. (VKTX) Stock Analysis: Exploring a Robust 194% Upside Potential

Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company headquartered in San Diego, California, has been capturing investor attention with its promising drug pipeline and significant..

Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Exploring a 10.94% Potential Upside with Strong Buy Ratings

Amneal Pharmaceuticals, Inc. (AMRX) is capturing the attention of investors with its promising financial outlook and a strong consensus of buy ratings from analysts. With a..

Immunovant, Inc. (IMVT) Stock Analysis: Biotech Potential with a 56% Upside

Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biotechnology company, has been capturing investor attention with its promising development pipeline in the healthcare sector. Based in New York,..

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring a Promising 166% Upside Potential

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stands as a notable player in the biotechnology sector, with a dedicated focus on developing treatments for rare and ultra-rare genetic..

Arcellx, Inc. (ACLX) Investor Outlook: Exploring a 73.20% Potential Upside in the Biotechnology Sector

For investors with a keen eye on the biotechnology sector, Arcellx, Inc. (NASDAQ: ACLX) presents an intriguing opportunity. Despite facing challenges typical of clinical-stage biotech companies,..

PROCEPT BioRobotics Corporation (PRCT) Stock Analysis: Healthcare Robotics with a 61.91% Upside Potential

Investors looking for opportunities in the healthcare sector might find PROCEPT BioRobotics Corporation (NASDAQ: PRCT) a compelling prospect, especially given its projected upside potential of 61.91%...

Privia Health Group, Inc. (PRVA) Stock Analysis: Exploring a 33% Upside Potential in Healthcare Innovation

Privia Health Group, Inc. (NASDAQ: PRVA), a prominent player in the healthcare sector, is making waves with its innovative approach to physician enablement. With a market..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds